0000000000770470

AUTHOR

Francis Guillemin

showing 6 related works from this author

Cross-cultural adaptation and validation of the French version of the Knee injury and Osteoarthritis Outcome Score (KOOS) in knee osteoarthritis pati…

2008

Udgivelsesdato: 2008-Apr OBJECTIVE: To adapt the Knee injury and Osteoarthritis Outcome Score (KOOS) into French and to evaluate the psychometric properties of this new version. METHODS: The French version of the KOOS was developed according to cross-cultural guidelines by using the "translation-back translation" method to ensure content validity. KOOS data were then obtained in patients with symptomatic knee osteoarthritis (OA). The translated questionnaire was evaluated in two knee OA population groups, one with no indication for joint replacement (medicine), and the other waiting for joint replacement (surgery). The psychometric properties evaluated were feasibility: percentage of respon…

QuestionnairesAdultCross-Cultural ComparisonMalemedicine.medical_specialtyPsychometricsPsychometricsJoint replacementmedicine.medical_treatmentCross-cultural validationPopulationBiomedical EngineeringOsteoarthritisSeverity of Illness IndexPhysical medicine and rehabilitationQuality of lifeCronbach's alphaRheumatologySurveys and QuestionnairesmedicineHumansTranslationsOrthopedics and Sports MedicineeducationAgedAged 80 and overeducation.field_of_studyKOOSbusiness.industryConstruct validityReproducibility of ResultsMiddle AgedOsteoarthritis Kneemedicine.diseasePhysical therapyQuality of LifeCeiling effectFemaleKnee osteoarthritisFrancebusinessOsteoarthritis and Cartilage
researchProduct

Factors Associated With Fatigue After Surgery in Women With Early-Stage Invasive Breast Cancer

2013

Abstract Learning Objectives Describe the effect of worsening fatigue after breast cancer surgery on physical functioning and psychological distress. Better identify women at risk for developing cancer-related fatigue. Direct target interventions to patients most in need. Purpose. Fatigue is one of the most frequent symptoms in patients with cancer. However, the precise determinants of fatigue are still unknown. This study was conducted to investigate factors correlated with cancer-related fatigue before surgery and just before subsequent adjuvant therapy. Methods. Patients completed the Multidimensional Fatigue Inventory (MFI-20), the European Organization for Research and Treatment of Can…

MESH: FatigueCancer ResearchMultivariate analysisMESH: Lymph NodesDisease0302 clinical medicineMESH: Aged 80 and overQuality of lifeSurveys and Questionnaires030212 general & internal medicineNeoplasm Metastasisskin and connective tissue diseasesFatigueAged 80 and overMESH: AgedMESH: Middle AgedMESH: Neoplasm StagingMiddle Aged3. Good healthOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisAnxietyMarital statusFemalemedicine.symptomAdultmedicine.medical_specialtyBreast Neoplasms03 medical and health sciencesBreast cancerAdjuvant therapymedicineHumansNeoplasm InvasivenessMESH: Surveys and QuestionnairesAgedNeoplasm StagingMESH: Humansbusiness.industryCancerMESH: Quality of LifeMESH: AdultMESH: Neoplasm Invasivenessmedicine.diseaseMESH: Neoplasm MetastasisSurgeryQuality of Life[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieLymph NodesbusinessMESH: FemaleMESH: Breast Neoplasms
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study.

2009

The aim of the longitudinal study PARTAGE (predictive values of blood pressure and arterial stiffness in institutionalized very aged population) was to determine the predictive value of blood pressure (BP) and arterial stiffness for overall mortality, major cardiovascular events and cognitive decline in a large population of institutionalized patients aged 80 and over. In the study herein, we present the baseline data values of this study.A total of 1130 patients were recruited (878 women), living in French and Italian nursing homes. Clinical and 3-day self-measurements of BP were conducted. Aortic and upper limb pulse wave velocity were obtained using a PulsePen tonometer.Of this populatio…

Malemedicine.medical_specialtyAgingPhysiologypulse wave velocityPopulationHemodynamicsBlood PressureHeart RatePredictive Value of TestsInternal medicineInternal MedicinemedicineHomes for the AgedHumansLongitudinal StudiesCognitive declineeducationPulse wave velocityAntihypertensive AgentsAortablodd pressure; pulse wave velocity; agingAged 80 and overblodd pressureeducation.field_of_studybusiness.industryBlood Pressure Determinationmedicine.diseasePulse pressureSurgeryNursing HomesSelf CareBlood pressureItalyPredictive value of testsPulsatile FlowBlood CirculationHypertensionArterial stiffnessCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessBlood Flow VelocityJournal of hypertension
researchProduct

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk…

2015

Summary Background The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Methods Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2…

MaleFine particulate matterNutrition and DiseaseMESH : SanitationHealth BehaviorDiseasesMESH: Metabolic DiseasesMESH: Global Health030204 cardiovascular system & hematologyMESH: Risk AssessmentGlobal HealthMESH : Nutritional StatusMESH: Occupational Exposure0302 clinical medicineUnsafe SexMESH: Risk FactorsRisk FactorsVoeding en ZiekteMedicineAir-pollutionMESH : Female030212 general & internal medicineMESH : Risk AssessmentSanitationWasting2. Zero hungerFactors de risc en les malaltiesMedicine (all)[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologiePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineMESH : Occupational DiseasesMESH: Nutritional StatusAll-cause mortalityMESH : Risk FactorshumanitiesEnvironmental Exposure; Female; Global Health; Health Behavior; Humans; Male; Metabolic Diseases; Nutritional Status; Occupational Diseases; Occupational Exposure; Risk Assessment; Risk Factors; Sanitation; Medicine (all)Tobacco smoking3. Good healthOccupational DiseasesNutritional StatuMESH : Occupational ExposureMESH : Metabolic DiseasesCohortFemalemedicine.symptomRisk assessmentBlood-pressureHumanMESH: Occupational DiseasesRisk factors in diseasesCoronary-heart-diseaseMESH : MaleMESH: Health BehaviorMESH: Environmental ExposureNutritional StatusPopulation healthBody-mass indexRisk Assessment03 medical and health sciencesHousehold cookingMetabolic DiseasesCardiovascular-diseaseEnvironmental healthGeneral & Internal MedicineOccupational Exposureparasitic diseasesLife ScienceMESH: SanitationHumansRisk factorMESH : Health BehaviorVLAGGBD2013MESH: Humansbusiness.industryRisk FactorGlobal Burden of Disease Study; 79 behavioural environmental and occupational and metabolic risksLong-term exposureMESH : HumansCAUSE-SPECIFIC MORTALITYEnvironmental ExposureMESH: MaleMetabolic DiseaseOccupational DiseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMALE BRITISH DOCTORSYears of potential life lostRelative riskMalaltiesMESH : Global HealthOUTDOOR AIR-POLLUTION[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH : Environmental ExposureMESH: FemaleLancet
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct